EVALUATION OF THE EFFICACY OF DEXMEDETOMIDINE IN COVID-19 DISEASE
Keywords:
Coronavirus, drug, COVID-19, dexmedetomidineAbstract
The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing global public health problem. Dexmedetomidine, sold under the trade name Precedex among others, is an anxiolytic, sedative and analgesic. Dexmedetomidine is notable for its ability to provide sedation without the risk of respiratory depression and can provide cooperative or semi-excitation.
References
Callaway E, Siranoski D, Mallapati S, Stoj E, Tollefson J. Coronavirus Pandemic in Five Powerful Diagrams. Nature 2020; 579:482e3
Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multi-organ response. Course Probl Cardiol 2020; 45:100618
Welz PS, Wullaert A, Vlantis K, et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011; 477:330e4
Grain J, Omagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382:2327e36
Vaduganathan M, Vardeni O, Michelle T, McMurray J. J. W., Pfeffer M. A., Solomon S. D. Reninangiotensin aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020; 382:1653e9
Su X, Meng ZT, Wu XH, et al. Dexmedetomidine for the prevention of delirium in elderly patients after non-cardiac surgery: a randomized, double-blind, placebo-controlled trial. Lancet 2016; 388:1893e902
Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: a systematic review and meta-analysis. Br J Anast 2019; 123:777e94
Sun Yu-B, Zhao X, Mu D-L et al. Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in in vitro and in vivo models of sepsis. Cell Death Dis 2019; 10:167
Ma J, Chen K, Li J, et al. Dexmedetomidine-mediated prevention of renal ischemia-reperfusion depends in part on cholinergic anti-inflammatory mechanisms. Anest Analg 2020; 130:1054e62
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
